

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

Brilliant Violet 421(TM) anti-human CD19

RRID:AB_10897802

Type: Antibody

Proper Citation

BioLegend Cat# 302233, RRID:AB_10897802

Antibody Information

URL: http://antibodyregistry.org/AB_10897802

Proper Citation: BioLegend Cat# 302233, RRID:AB_10897802

Target Antigen: CD19

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC, ICC, IHC-F

Antibody Name: Brilliant Violet 421(TM) anti-human CD19

Description: This monoclonal targets CD19

Target Organism: human

Clone ID: Clone HIB19

Antibody ID: AB_10897802

Vendor: BioLegend

Catalog Number: 302233

Alternative Catalog Numbers: 302234

Record Creation Time: 20250820T025537+0000

Record Last Update: 20250820T145303+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 421(TM) anti-human CD19.

No alerts have been found for Brilliant Violet 421(TM) anti-human CD19.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Pulliam T, et al. (2024) Circulating cancer-specific CD8 T cell frequency is associated with response to PD-1 blockade in Merkel cell carcinoma. *Cell reports. Medicine*, 5(2), 101412.

Cheung A, et al. (2024) Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(15), 3298.

Irrgang P, et al. (2023) Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. *Science immunology*, 8(79), eade2798.

Fabra-García A, et al. (2023) Highly potent, naturally acquired human monoclonal antibodies against Pfs48/45 block *Plasmodium falciparum* transmission to mosquitoes. *Immunity*, 56(2), 406.

Chauvin C, et al. (2023) Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants. *iScience*, 26(3), 106124.

García-Vega M, et al. (2023) 19n01, a broadly neutralizing antibody against omicron BA.1, BA.2, BA.4/5, and other SARS-CoV-2 variants of concern. *iScience*, 26(4), 106562.

Stražar M, et al. (2023) HLA-II immunopeptidome profiling and deep learning reveal features of antigenicity to inform antigen discovery. *Immunity*, 56(7), 1681.

de Silva TI, et al. (2021) The impact of viral mutations on recognition by SARS-CoV-2 specific T cells. *iScience*, 24(11), 103353.

Cizmeci D, et al. (2021) Distinct clonal evolution of B-cells in HIV controllers with neutralizing antibody breadth. *eLife*, 10.

Schoofs T, et al. (2019) Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. *Immunity*, 50(6), 1513.

Usmani SM, et al. (2019) HIV-1 Balances the Fitness Costs and Benefits of Disrupting the Host Cell Actin Cytoskeleton Early after Mucosal Transmission. *Cell host & microbe*, 25(1), 73.